New Jersey Drugmaker Hit for Litany of Issues, Including OOS Management

Drug Industry Daily
A A
The FDA cited Lupin’s Novel Laboratories facility in Somerset, New Jersey, for its handling of out-of-specification results and other violations observed in a Dec. 3-21, 2018 inspection. 

To View This Article:

Login

Subscribe To Drug Industry Daily